Skip to main content
Journal cover image

Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000-2021.

Publication ,  Journal Article
Kwon, J; Pelletiers, W; Galloway Peña, J; van Duin, D; Ledbetter, L; Baum, K; Ruffin, F; Knisely, JM; Bizzell, E; Fowler, VG; Chambers, HF ...
Published in: Clin Infect Dis
July 19, 2024

BACKGROUND: Equitable representation of members from historically marginalized groups is important in clinical trials, which inform standards of care. The goal of this study was to characterize the demographics and proportional subgroup reporting and representation of participants enrolled in randomized controlled trials (RCTs) of antibacterials used to treat Staphylococcus aureus infections. METHODS: We examined randomized controlled registrational and strategy trials published from 2000 to 2021 to determine the sex, race, and ethnicity of participants. Participant to incidence ratios (PIRs) were calculated by dividing the percentage of study participants in each demographic group by the percentage of the disease population in each group. Underrepresentation was defined as a PIR < 0.8. RESULTS: Of the 87 included studies, 82 (94.2%) reported participant sex, 69 (79.3%) reported participant race, and 20 (23.0%) included ethnicity data. Only 17 (19.5%) studies enrolled American Indian/Alaskan Native participants. Median PIRs indicated that Asian and Black participants were underrepresented in RCTs compared with the incidence of methicillin-resistant S. aureus infections in these subgroups. Underrepresentation of Black participants was associated with a larger study size, international sites, industry sponsorship, and phase 2/3 trials compared with phase 4 trials (P < .05 for each). Black participants had more than 4 times the odds of being underrepresented in phase 2/3 trials compared with phase 4 trials (odds ratio, 4.57; 95% confidence interval: 1.14-18.3). CONCLUSIONS: Standardized reporting methods for race and ethnicity and efforts to increase recruitment of marginalized groups would help ensure equity, rigor, and generalizability in RCTs of antibacterial agents and reduce health inequities.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

July 19, 2024

Volume

79

Issue

1

Start / End Page

141 / 147

Location

United States

Related Subject Headings

  • United States
  • Staphylococcus aureus
  • Staphylococcal Infections
  • Randomized Controlled Trials as Topic
  • Racial Groups
  • Microbiology
  • Male
  • Humans
  • Female
  • Ethnicity
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kwon, J., Pelletiers, W., Galloway Peña, J., van Duin, D., Ledbetter, L., Baum, K., … Pettigrew, M. M. (2024). Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000-2021. Clin Infect Dis, 79(1), 141–147. https://doi.org/10.1093/cid/ciae049
Kwon, Jiye, William Pelletiers, Jessica Galloway Peña, David van Duin, Leila Ledbetter, Keri Baum, Felicia Ruffin, et al. “Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000-2021.Clin Infect Dis 79, no. 1 (July 19, 2024): 141–47. https://doi.org/10.1093/cid/ciae049.
Kwon J, Pelletiers W, Galloway Peña J, van Duin D, Ledbetter L, Baum K, et al. Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000-2021. Clin Infect Dis. 2024 Jul 19;79(1):141–7.
Kwon, Jiye, et al. “Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000-2021.Clin Infect Dis, vol. 79, no. 1, July 2024, pp. 141–47. Pubmed, doi:10.1093/cid/ciae049.
Kwon J, Pelletiers W, Galloway Peña J, van Duin D, Ledbetter L, Baum K, Ruffin F, Knisely JM, Bizzell E, Fowler VG, Chambers HF, Pettigrew MM. Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000-2021. Clin Infect Dis. 2024 Jul 19;79(1):141–147.
Journal cover image

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

July 19, 2024

Volume

79

Issue

1

Start / End Page

141 / 147

Location

United States

Related Subject Headings

  • United States
  • Staphylococcus aureus
  • Staphylococcal Infections
  • Randomized Controlled Trials as Topic
  • Racial Groups
  • Microbiology
  • Male
  • Humans
  • Female
  • Ethnicity